16th November 2020

Consilium Strategic Communications, Citi Depositary Receipt Services, Cooley and Stifel hosted Virtual Annual Healthcare Conference on 16th November 2020

Panel: The impact of COVID-19 on the future of healthcare

Fireside chat: The FT’s Clive Cookson speaking to Jan van de Winkel, President & Chief Executive Officer, Genmab

On the 16 November 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, together with Citi Depositary Receipt Services, Cooley and Stifel hosted it’s eighth Annual Healthcare Conference today, for the first time in a virtual format.

We had 250 registrants join us on the day and even more downloading the replay.

The main panel session focussed on the impact of COVID-19 on the healthcare industry in 2020 and beyond – from operational learnings and clinical trial progress, to the investment landscape and changing public perception of the industry.

The panellists agreed that while innovation has never been lacking in our sector, the virtually unlimited funding and incredible will to make a difference in the face of a global health crisis, accelerated the pace of innovation to unprecedented levels in 2020.

The panellists represented the full range of the industry:

  • Moderator: Josh Schimmer, Biotech Equity Research Analyst, Evercore ISI
  • Hugo Fry, Managing Director, Sanofi UK
  • George Goldsmith, Chairman, Chief Executive Officer and Co-Founder, COMPASS Pathways
  • Rachel Mears, Partner, Jeito Capital
  • Linden Thomson, Lead Manager, AXA Framlington Biotech Fund
  • Anne E. White, Senior Vice President of Eli Lilly and Company and President of Lilly Oncology
  • Professor Tom Wilkinson, Professor of Respiratory Medicine University of Southampton, Co-Founder, my mHealth; Trial Chief Investigator of Synairgen’s SNG001

Following the panel, Genmab’s President & Chief Executive Officer Jan van de Winkel was interviewed by Clive Cookson, Science Editor of the Financial Times. Jan shared insights from his years at the helm of Genmab, explored how the company adapted in light of all the challenges posed by the pandemic, and his hopes for the future. “We aim to be an integrated powerhouse, and to continue to innovate and to have a positive impact on as many cancer patients as possible,” he concluded.

We hope you enjoy the video and we will hopefully see you again at next year’s conference!

Back to previous page